Semax

Semax is the cognitive companion to Selank in the Russian peptide cluster, and the two share an asymmetric evidence base. Semax has been on the Russian List of Vital and Essential Drugs since 1995, with regulatory approval for acute ischemic stroke, transient ischemic attack, post-stroke cognitive rehabilitation, optic-nerve atrophy, and several cognitive and ophthalmic indications. The clinical formulation is 0.1% intranasal drops, and the route choice operationalizes the Manchenko 2010 route-dissociation finding rather than reflecting a tolerability default. The Russian clinical literature is substantial — the landmark Gusev / Skvortsova trial in 1997 examined Semax (12–18 mg/day, 5–10 days) added to combined intensive therapy in 30 acute hemispheric ischemic stroke patients versus 80 conventionally treated controls, reporting accelerated regression of motor and general cerebral deficits with EEG and somatosensory evoked potential correlates. Subsequent Russian trials in stroke rehabilitation, optic neuropathy, and cognitive aging have continued to be published in domestic journals, with intermittent indexing in PubMed via translated abstracts.

The full corpus evidence chronology for Semax now spans:

• Kaplan et al. 1996 — the foundational international publication of cognitive and EEG effects in healthy human volunteers, with a 20-24 hour single-dose carry-over in operator performance and the pharmaco-EEG signature (alpha up, delta down) the authors classify as nootropic
• Kost et al. 2001 — the opioidergic mechanism shared with Selank, with the inhibitory activity localized to the C-terminal Pro-Gly-Pro extension
• Eremin et al. 2005 — the Western-indexed monoaminergic mechanism study, with the dopamine-amplification finding that anchors the stimulant-interaction caution downstream
• Levitskaya et al. 2008 — the decade-on synthesis review tying nootropic, neuroprotective, anxiolytic, antidepressant, analgesic, and developmental effects to a melanocortin + BDNF + monoaminergic substrate
• Manchenko et al. 2010 — the route-dissociation primary study in rats, the operational basis for the intranasal clinical convention
• Vasileva et al. 2020 — the Zakusov Institute mouse-strain replication extending the route-asymmetry pattern to Selank and surfacing the BALB/c-versus-C57BL/6 strain dependence

The honest framing matches Selank's: the evidence base is real but parallel to, not overlapping with, the standards used to approve neurological drugs in the United States or European Union. The Russian primary literature is substantive within its own tradition — three decades of clinical and mechanistic work across multiple Russian research centers — and the mechanistic case is now considerably better-characterized than the typical English-language "Semax is poorly studied" framing acknowledges. The remaining gap is independent Western RCT replication, which has not happened and is not currently funded. Most of what is asserted about Semax in English-language wellness writing rests on a Russian clinical literature that has been only patchily translated and that does not generally meet contemporary FDA or EMA methodological standards. Treat Semax as a peptide with a moderately-developed parallel-literature evidence base, a coherent three-mechanism story (opioidergic via Pro-Gly-Pro, BDNF / monoaminergic via melanocortin substrate, route-conditional via nose-to-brain delivery), and the central clinical limitation that the trial cohort sizes remain small and Western-replicated.

The intranasal route choice deserves explicit attention because it is one of the cleanest examples in the peptide literature of route specificity being mechanism-driven rather than convention. The Manchenko 2010 dissociation specifies why Semax is administered intranasally for cognitive indications — systemic exposure recruits descending analgesic circuitry that intranasal delivery bypasses, and matched-dose intranasal Semax produces a stronger nootropic effect than intraperitoneal. The cognitive enhancement decision guide walks the broader cognitive-peptide class context; the injection technique doesn't matter critic-response addresses the more general claim that route is interchangeable, which the Semax data falsifies cleanly.